These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 6345667)

  • 41. Enhanced survival of skin grafts depleted of Langerhans' cells by treatment with dimethylbenzanthracene.
    Odling KA; Halliday GM; Muller HK
    Immunology; 1987 Nov; 62(3):379-85. PubMed ID: 3117676
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Abrogation of T cell homing by alloantibody.
    Chang AE; Sugarbaker PH
    Transplantation; 1980 Feb; 29(2):127-32. PubMed ID: 6986686
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of passive enhancement on graft and host. Graft adaptation by alloantibody as the mechanism of prolonged skin allograft survival.
    McCullough CS; Sugarbaker PH; Matthews W
    Transplantation; 1984 Jan; 37(1):91-6. PubMed ID: 6229914
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hyperacute rejection of skin allografts in the mouse. Sensitivity of ingrowing skin grafts to the action of alloantibody and rabbit complement.
    Gerlag PG; Koene RA; Hagemann JF; Wijdeveld PG
    Transplantation; 1975 Oct; 20(4):308-13. PubMed ID: 1099736
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts.
    Jindra PT; Hsueh A; Hong L; Gjertson D; Shen XD; Gao F; Dang J; Mischel PS; Baldwin WM; Fishbein MC; Kupiec-Weglinski JW; Reed EF
    J Immunol; 2008 Feb; 180(4):2214-24. PubMed ID: 18250428
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evolution of alloantibodies and suppressor cells in allografted mice treated for passive enhancement.
    Duc HT; Kinsky RG; Monnot P; Voisin GA
    Cell Immunol; 1985 Oct; 95(1):180-94. PubMed ID: 4028170
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prolonged skin allograft survival through enhancement effects on donor tissue.
    Deutsch HL; Edington HD; McCullough CM; Sugarbaker PH
    Transplantation; 1986 Aug; 42(2):200-4. PubMed ID: 3526658
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prolonged skin graft survival with antityphoid sera.
    Kolker P; Mandell C
    Surg Forum; 1972; 23(0):308-9. PubMed ID: 4601094
    [No Abstract]   [Full Text] [Related]  

  • 49. Absence of requirement for polymorphonuclear granulocytes in the acute antibody-mediated rejection of murine skin allografts.
    Bogman MJ; Cornelissen IM; Koene RA
    Transplantation; 1984 Apr; 37(4):402-5. PubMed ID: 6369672
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Enhancing alloantibody effective during sensitization but not effector phase of skin graft rejection.
    Sugarbaker PH; Chang AE
    Transplantation; 1979 Jul; 28(1):60-5. PubMed ID: 377597
    [No Abstract]   [Full Text] [Related]  

  • 51. Enhancement of skin allograft survival by soluble alloantigen is serum-mediated.
    Rao VS; Bonavida B
    Transplantation; 1976 Jan; 21(1):42-50. PubMed ID: 1108325
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of idarubicin monoclonal antibody treatment of first-set rejection of murine skin allografts.
    Smyth MJ; McKenzie IF; Pietersz GA
    Transplantation; 1989 Jul; 48(1):77-9. PubMed ID: 2665240
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Effect of a specific alloantiserum against T-suppressor cells on the resistance of mice to tuberculosis].
    Apt AS; Abramova ZP; Moroz AM; Nikonenko BV; Averbakh MM
    Biull Eksp Biol Med; 1983 May; 95(5):78-81. PubMed ID: 6221770
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of Lyt-2 mAb on murine skin graft survivals.
    Ichikawa T; Nakayama E; Uenaka A; Monden M; Okamura J; Mori T
    Transplant Proc; 1987 Feb; 19(1 Pt 1):579-81. PubMed ID: 3547829
    [No Abstract]   [Full Text] [Related]  

  • 55. Passive allograft enhancement by subclasses of polyclonal antibodies directed toward restricted regions of the major histocompatibility complex.
    Duc HT; Kinsky RG; Voisin GA
    Transplantation; 1982 May; 33(5):492-9. PubMed ID: 6806954
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Skin graft enhancement studies with antigenic differences arising from the H-2K, H-2D, and H-2L loci.
    McKenzie IF; Henning MM; Morgan GM
    Transplantation; 1980 Jun; 29(6):439-43. PubMed ID: 6996234
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Unimpaired first-set and second-set skin graft rejection in agammaglobulinemic mice.
    Cerny A; Ramseier H; Bazin H; Zinkernagel RM
    Transplantation; 1988 Jun; 45(6):1111-3. PubMed ID: 3289151
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Procedure for the isolation of mouse anti H-2 antibodies from complex alloantisera.
    De Waal RM; Koene RA
    J Immunol Methods; 1977; 14(3-4):225-9. PubMed ID: 402423
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antigen-reactive cell opsonization (ARCO) and its role in antibody-mediated immune suppression.
    Hutchinson IV
    Immunol Rev; 1980; 49():167-97. PubMed ID: 6154641
    [No Abstract]   [Full Text] [Related]  

  • 60. Retransplantation of murine skin allografts: assessment of treatment effects on the allograft in the absence of effects on the host.
    Sugarbaker PH; McCullough CS; Deutsch HL
    J Immunol Methods; 1984 Sep; 72(2):361-6. PubMed ID: 6381600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.